Key result
Levosimendan improves hemodynamics and increases cardiac output compared to dobutamine in decompensated heart failure, although recent large trials have not confirmed a mortality benefit.
Why the study?
Does levosimendan improve outcomes compared to or in combination with dobutamine in patients with decompensated heart failure?
Population
Patients with decompensated heart failure
Comparison
Levosimendan vs Dobutamine
Design
Review
Authors
Loading...
May favor levosimendan for acute hemodynamics in beta-blocked decompensated HF; leaves open mortality benefit and combination strategies.
Does levosimendan improve outcomes compared to or in combination with dobutamine in patients with decompensated heart failure?
Levosimendan offers favorable hemodynamic effects compared to dobutamine in decompensated heart failure, particularly in patients on beta-blockers or with ischemic heart disease, and may be useful in combination with dobutamine for refractory cases.
Yüksel Çavuşoğlu (2007) conducted a review in decompensated heart failure. Levosimendan vs. Dobutamine was evaluated. Levosimendan improves hemodynamics and increases cardiac output compared to dobutamine in decompensated heart failure, although recent large trials have not confirmed a mortality benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: